Surgery While on — Bevacizumab: The 28-Day Rule

The 28-day figure comes from bevacizumab's pharmacokinetics and clinical experience with wound complications. With a half-life of roughly 20 days, a 28-day pause allows most of the drug to clear while keeping the surgical delay as short as possible. It is a pragmatic consensus threshold from NCCN and ASCO guidance rather than a precise biological cut-off. Some surgeons and oncologists extend the pause to six weeks for higher-risk procedures, such as major abdominal operations. Your team may adjust it based on the specific surgery and your overall situation.

Emergency surgery takes priority over the pause. If an operation cannot wait, your surgical team needs to know you are on bevacizumab before they begin — even if there has been no pause. They can use surgical techniques that reduce the wound-healing risk, such as specific closure methods or drains, and they will monitor the wound more closely afterwards. The anaesthetist also needs to know, because bevacizumab can affect blood pressure control during surgery. Delaying an emergency operation to complete a drug pause is never the right decision.

It depends on the procedure. Minor procedures performed under image guidance with a needle, such as a core biopsy, carry a lower wound-healing risk than open surgery, and your oncologist may decide a shorter pause — or no pause — is acceptable. A port insertion or removal involves a surgical incision and is more likely to need a pause, even though it feels routine. Ask your oncologist specifically about the procedure you are having and do not assume a small operation is automatically exempt.

A planned pause of 28 days is generally considered acceptable and does not undo the treatment you have had. Bevacizumab is typically part of a multi-drug regimen, and some of your other medicines may continue during the pause if your oncologist decides that is appropriate. If your cancer is responding well and surgery is the immediate priority, a structured pause is the safer path. Your oncologist will explain what is being held and why, and for how long the overall treatment course may be extended.

Signs to watch for include a wound that does not appear to be closing after the first week, wound edges that separate after seeming healed, pain that is increasing rather than decreasing around the wound, discharge that is not reducing, or any redness spreading beyond the wound edges. None of these is a reason to wait for your next scheduled appointment. Call your surgical team the same day and mention that you are on or were recently on bevacizumab when you call.

They should speak to each other directly, or at minimum exchange written notes. Passing information verbally between teams introduces the risk that critical details are lost or misunderstood. The restart decision in particular — when it is safe to resume bevacizumab after surgery — requires input from both your surgeon, who can assess wound healing, and your oncologist, who is managing your cancer. If you are unsure whether this coordination has happened, ask both teams the same question: 'Have you spoken with the other team about my bevacizumab timing?'